Back to search results

Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic Sclerosis

Israel
RecruitingPHASE2

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Conditions

Scleroderma, Diffuse

Locations
  • UCLA, Los Angeles, California, United States
  • UCSF, San Francisco, California, United States
  • UCSF, San Francisco, California, United States
  • Sutter Health Network, San Pablo, California, United States
  • FL Medical Clinic Orlando Health, Zephyrhills, Florida, United States
  • Northwestern University, Chicago, Illinois, United States
  • University Of Iowa, Iowa City, Iowa, United States
  • Boston Medical Center, Boston, Massachusetts, United States
  • Michigan Med University of Michigan, Ann Arbor, Michigan, United States
  • University of Minnesota, Minneapolis, Minnesota, United States
  • James Cancer Hospital, Columbus, Ohio, United States
  • Oregon Health Sciences University, Portland, Oregon, United States
  • Avera Cancer, Sioux Falls, South Dakota, United States
  • LDS Hospital, Salt Lake City, Utah, United States
  • Novartis Investigative Site, Camperdown, New South Wales, Australia
  • Novartis Investigative Site, Darlinghurst, New South Wales, Australia
  • Novartis Investigative Site, Graz, Austria
  • Novartis Investigative Site, Vienna, Austria
  • Novartis Investigative Site, São Paulo, São Paulo, Brazil
  • Novartis Investigative Site, Olomouc, Czechia
  • Novartis Investigative Site, Prague, Czechia
  • Novartis Investigative Site, Aarhus N, Denmark
  • Novartis Investigative Site, Bordeaux, France
  • Novartis Investigative Site, Dijon, France
  • Novartis Investigative Site, Lille, France
  • Novartis Investigative Site, Lyon, France
  • Novartis Investigative Site, Montpellier, France
  • Novartis Investigative Site, Paris, France
  • Novartis Investigative Site, Rennes, France
  • Novartis Investigative Site, Freiburg im Breisgau, Baden-Wurttemberg, Germany
  • Novartis Investigative Site, Göttingen, Lower Saxony, Germany
  • Novartis Investigative Site, Leipzig, Saxony, Germany
  • Novartis Investigative Site, Halle, Saxony-Anhalt, Germany
  • Novartis Investigative Site, Jena, Thuringia, Germany
  • Novartis Investigative Site, Berlin, Germany
  • Novartis Investigative Site, Mainz, Germany
  • Novartis Investigative Site, Nuremberg, Germany
  • Novartis Investigative Site, Ulm, Germany
  • Novartis Investigative Site, Debrecen, Hajdu Bihar Megye, Hungary
  • Novartis Investigative Site, Budapest, Hungary
  • Novartis Investigative Site, Haifa, Israel
  • Novartis Investigative Site, Ramat Gan, Israel
  • Novartis Investigative Site, Tel Aviv, Israel
  • Novartis Investigative Site, Ancona, AN, Italy
  • Novartis Investigative Site, Bergamo, BG, Italy
  • Novartis Investigative Site, Brescia, BS, Italy
  • Novartis Investigative Site, Genova, GE, Italy
  • Novartis Investigative Site, Milan, MI, Italy
  • Novartis Investigative Site, Milan, MI, Italy
  • Novartis Investigative Site, Pescara, PE, Italy
  • Novartis Investigative Site, Perugia, PG, Italy
  • Novartis Investigative Site, Pisa, PI, Italy
  • Novartis Investigative Site, Pavia, PV, Italy
  • Novartis Investigative Site, Roma, RM, Italy
  • Novartis Investigative Site, Udine, UD, Italy
  • Novartis Investigative Site, Sapporo, Hokkaido, Japan
  • Novartis Investigative Site, Kanazawa, Ishikawa-ken, Japan
  • Novartis Investigative Site, Sendai, Miyagi, Japan
  • Novartis Investigative Site, Suita, Osaka, Japan
  • Novartis Investigative Site, Bunkyo-ku, Tokyo, Japan
  • Novartis Investigative Site, Fukuoka, Japan
  • Novartis Investigative Site, Kyoto, Japan
  • Novartis Investigative Site, Utrecht, Netherlands
  • Novartis Investigative Site, Singapore, Singapore
  • Novartis Investigative Site, Seoul, South Korea
  • Novartis Investigative Site, Santiago Compostela, A Coruna, Spain
  • Novartis Investigative Site, Santander, Cantabria, Spain
  • Novartis Investigative Site, Pamplona, Navarre, Spain
  • Novartis Investigative Site, Barcelona, Spain
  • Novartis Investigative Site, Barcelona, Spain
  • Novartis Investigative Site, Córdoba, Spain
  • Novartis Investigative Site, Madrid, Spain
  • Novartis Investigative Site, Madrid, Spain
  • Novartis Investigative Site, Málaga, Spain
  • Novartis Investigative Site, Salamanca, Spain
  • Novartis Investigative Site, Valencia, Spain
  • Novartis Investigative Site, Geneva, Switzerland
  • Novartis Investigative Site, Lausanne, Switzerland
  • Novartis Investigative Site, Zurich, Switzerland
  • Novartis Investigative Site, Taichung, Taiwan
View source on ClinicalTrials.gov(opens in a new tab)Contact study team (email)